SCIENTURE ISSUES SHAREHOLDER LETTER HIGHLIGHTING SEQUENTIAL REVENUE GROWTH, TWO FDA-APPROVED COMMERCIAL PRODUCTS, AND CONTINUED PROGRESS TOWARD PROFITABILITY IN 2027

Reuters · 2d ago

Please log in to view news